A double blind study to compare the acute and subchronic effects of ebastine 10, 20 and 30 mg o.d., triprolidine 10 mg o.d. and placebo on car driving performance.

Author(s)
Vries, G. de Waard, D. de & Brookhuis, K.A.
Year
Abstract

Ebastine is a recently developed potent and selective H1- receptor antagonist for treatment of seasonal and perennial allergic rhinitis and idiopathic urticaria. In the present study 15 male subjects participated in testing the effects of ebastine 30, 20 and 10 mg o.d., triprolidine 10 mg o.d. and placebo on a standard driving test and on car following performance. The conclusion of this experiment is that ebastine up to 30 mg o.d. does not seem to impair safe driving behaviour.

Request publication

20 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Publication

Library number
B 30393 [electronic version only] /83 / IRRD 832992
Source

Haren, Rijksuniversiteit Groningen RUG, Verkeerskundig Studiecentrum VSC, 1989, 47 p., 30 ref.; VK 89-22

Our collection

This publication is one of our other publications, and part of our extensive collection of road safety literature, that also includes the SWOV publications.